Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

# Label-free imaging for quality control of cardiomyocyte differentiation

## Abstract

Human pluripotent stem cell (hPSC)-derived cardiomyocytes provide a promising regenerative cell therapy for cardiovascular patients and an important model system to accelerate drug discovery. However, cost-effective and time-efficient platforms must be developed to evaluate the quality of hPSC-derived cardiomyocytes during biomanufacturing. Here, we develop a non-invasive label-free live cell imaging platform to predict the efficiency of hPSC differentiation into cardiomyocytes. Autofluorescence imaging of metabolic co-enzymes is performed under varying differentiation conditions (cell density, concentration of Wnt signaling activator) across five hPSC lines. Live cell autofluorescence imaging and multivariate classification models provide high accuracy to separate low (< 50%) and high (≥ 50%) differentiation efficiency groups (quantified by cTnT expression on day 12) within 1 day after initiating differentiation (area under the receiver operating characteristic curve, 0.91). This non-invasive and label-free method could be used to avoid batch-to-batch and line-to-line variability in cell manufacturing from hPSCs.

## Introduction

Despite advances in treatment, cardiovascular disease is the leading cause of death worldwide1. Globally, about 12% of adults are diagnosed with cardiovascular disease and over 30% of all deaths are caused by cardiovascular disease1. The excessive demand of heart transplantation has outpaced the limited number of healthy and functional heart donors2. Cell-based regenerative therapy provides a promising treatment for patients suffering from cardiac tissue injury3,4. However, cardiomyocytes (CMs) are terminally differentiated cells with no regenerative capacity5. Hence, cost-effective and time-efficient platforms to generate functional CMs with high quality has emerged as an urgent need for cardiac medicine in drug screening, toxicity testing, disease modeling, and regenerative cell therapy.

Human pluripotent stem cells (hPSCs) can differentiate into cells from all three germ layers6,7,8. A variety of methods have been established to generate CMs from hPSCs9,10,11. These hPSC-derived CMs exhibit similar functional phenotypes to their in vivo counterparts11, including self-contractility and action potentials. hPSC-derived CMs have been used in disease modeling12,13 and drug screening14, and hold great potential for regenerative medicine15,16. However, batch-to-batch and line-to-line variability in the differentiation process of hPSCs into CMs has impeded the scale-up of CM manufacturing17. For safety, the quality of clinical-graded hPSC-derived CMs must be rigorously evaluated before they can be used for regenerative cell therapy in patients18. Current approaches to quantify CM differentiation rely on low-throughput, labor-intensive, and destructive immunofluorescence labeling and electrophysiological measurements11. New technologies that can non-invasively monitor CM differentiation in real time and evaluate the differentiation outcome at early stages are needed to effectively optimize the biomanufacturing of CMs from stem cells.

The goal of this study is to build a predictive model based on OMI to determine whether OMI can predict CM differentiation efficiency early in the differentiation process. Early prediction of CM differentiation outcome can benefit CM manufacturing. We demonstrate a facile method to non-invasively monitor metabolic changes during hPSC differentiation into CMs by combining OMI with quantitative image analysis. OMI is performed at multiple time points during a 12-day differentiation process under varying conditions (cell density, concentration of Wnt signaling activator) and different hPSC lines (human embryonic pluripotent stem cells and human induced pluripotent stem cells). Differentiation efficiency is quantified by flow cytometry with cTnT labeling on day 12. During the differentiation process all 13 OMI variables, including both NAD(P)H and FAD intensity and lifetime variables, change distinctively between low (< 50% cTnT+ on day 12) and high (≥ 50% cTnT+ on day 12) CM differentiation efficiency conditions. Multivariate analysis finds that day 1 cells (24 h after Wnt activation) form a distinct cluster from cells at other time points. Logistic regression models based on OMI variables from cells at day 1 perform well for separating low and high differentiation efficiency conditions with a model performance at 0.91 (receiver operating characteristic (ROC) area under the curve (AUC)). Compared to previous studies23,24,25,26,27,28, we specifically contribute a predictive model based on OMI to determine CM differentiation outcome as early as day 1. This label-free and non-destructive method could be used for quality control for CM manufacturing from hPSCs.

## Results

### NAD(P)H and FAD fluorescence change early in the cardiomyocyte differentiation process

Metabolic state plays an important role in regulating hPSC pluripotency and differentiation29,30, and can be non-invasively monitored via OMI20,24. We recorded the autofluorescence dynamics of NAD(P)H and FAD by OMI during the process of hPSC differentiation into CMs. hPSCs were differentiated following a previous protocol11, and cells were imaged on differentiation day 0 (immediately pre-treatment with CHIR99021, a Wnt signaling activator), day 1 (24 h post-treatment with CHIR99021), day 3 (immediately pre-treatment with IWP2, a Wnt signaling inhibitor), and day 5 (48 h post-treatment with IWP2). OMI was performed at these time points based on the biphasic role of Wnt signaling activation and inhibition in the CM differentiation protocol11 (Supplementary Fig. 1a). On differentiation day 12, CM differentiation efficiencies were evaluated by flow cytometry with a cardiac specific marker cTnT. Differentiation of CMs from hPSCs critically relies on the timing and the state of Wnt signaling11. Both the concentration of CHIR9902131 and cell density7 are closely related to the activation level of the Wnt signaling pathway. In the current study, CM differentiation efficiencies ranging from nearly 0 to above 60% were achieved by initiating CM differentiation with different CHIR99021 concentrations and hPSC seeding densities (Fig. 1a, b, Table 1).

### Multivariate analysis reveals unique NAD(P)H and FAD fluorescence in cells 1 day into the differentiation process

To assess differences in OMI variables across days, cells were clustered across all days (day 0, day 1, day 3, and day 5) and differentiation conditions (Table 1) with a Uniform Manifold Approximation and Projection (UMAP) dimension reduction technique35. UMAP dimensionality reduction was performed on all 13 OMI variables for projection onto 2D space. UMAP representations of all OMI variables showed a day 1 subpopulation separated from days 0, 3, 5 (Fig. 2a, Supplementary Fig. 2). CM differentiation efficiency conditions were separately evaluated across all days by UMAP. As shown in Fig. 2c, day 1 cells (light blue clusters) from high (≥ 50%) differentiation efficiency conditions were distinctly clustered, while cells from low (< 50%) differentiation efficiency conditions clustered together across all days. Therefore, differentiation conditions were separated into low differentiation efficiency (< 50% cTnT+ on day 12, Table 1 in italic) and high differentiation efficiency (≥ 50% cTnT+ on day 12, Table 1 in bold).

Heatmap dendrogram clustering based on OMI variable z-scores revealed that cells under high differentiation efficiency conditions on day 1 were clustered closely together and distinct from cells under low differentiation efficiency conditions on day 1 (Fig. 2b) except the 61.0% differentiation efficiency with 6 μM CHIR treatment for 19-9-11 hPSCs. This outlier could be due to multiple reasons, e.g., the low CHIR99021 concentration or low cell seeding density. In the future, more variables, such as cell morphology, can be introduced to increase linear clustering performance. Dendrograms of cells on day 0 and day 1 together (Supplementary Fig. 3a) or day 0 alone (Supplementary Fig. 3b) did not show clear separation of high and low differentiation efficiency conditions, indicating that day 1 is the earliest time point to separate low and high differentiation efficiency conditions. In summary, UMAP clustering of all 13 OMI variables across all time points and z-score heatmap clustering from day 0 and day 1 across all differentiation conditions showed that cells under high differentiation efficiency conditions on day 1 clustered together and were distinct from other conditions and time points. Hence, we hypothesize that OMI of live cells on CM differentiation day 1 could predict high and low differentiation efficiencies on day 12.

### OMI variables accurately distinguish cells under low or high differentiation efficiency conditions on day 1

After identifying distinct clustering of day 1 cells in high differentiation efficiency conditions based on all 13 OMI variables, we further explored day 1 OMI data alone. Cells in high differentiation efficiency conditions (Fig. 3a, dark gray, ≥ 50% cTnT+ on day 12) formed a distinct cluster from cells under low differentiation efficiency conditions (Fig. 3a, light gray, < 50% cTnT+ on day 12) on day 1. However, a small portion of cells from high and low differentiation efficiency conditions overlap. Note that the high differentiation efficiency conditions were not 100% and the low differentiation efficiency conditions were not 0%, so this could explain some of the overlap on day 1.

### Imaging of a cardiac reporter line confirms autofluorescence changes in cells under high differentiation efficiency conditions

Given that OMI can identify CM differentiation efficiency at an early stage, we evaluated a CM reporter line (NKX2.5EGFP/+ hPSCs)36 to track differentiated CMs together with autofluorescence imaging during the entire differentiation process. The NKX2.5EGFP/+ hPSC line expresses EGFP when the cardiac progenitor protein NKX2.5 is expressed, indicating that the cell has differentiated into CM, around differentiation day 7. Although EGFP spectrally overlaps with FAD autofluorescence signals, this interference does not occur until day seven36. The final differentiation efficiency was quantified by flow cytometry with cTnT labeling (Fig. 4a). Approximately 0.3% and 84.1% CMs were yielded with 12 µM and 9 µM CHIR99021 treatment, respectively.

Differences in OMI variables between low (0.3%) and high (84.1%) differentiation efficiencies were assessed with this reporter line. Consistent with the observations in Fig. 1c and d, NAD(P)H τm (Fig. 4b–d) and FAD τm (Fig. 4e–g) were significantly different between low vs. high differentiation efficiency conditions on day 0 and day 1 with the CM reporter line. In both conditions, NAD(P)H τm gradually decreased over the first 5 days of differentiation (Supplementary Fig. 5a). Conversely, FAD τm gradually increased over the first 5 days for the high differentiation efficiency condition and oscillated over time for the low differentiation efficiency condition (Supplementary Fig. 5b). These observations are consistent with our previous findings (Fig. 1, Supplementary Fig. 1b) using 11 differentiation conditions across two hPSC lines.

## Discussion

Here, we report a non-invasive label-free imaging method to predict the outcome of hPSC differentiation into CMs. By combining live cell autofluorescence lifetime imaging, single-cell image analysis, and machine learning, we robustly separate low (< 50%) from high (≥ 50%) CM differentiation efficiency conditions as early as day 1. The prediction accuracy was over 85% and the model performance was 0.91 (AUC of ROC) with all 13 OMI variables combined across 15 different differentiation conditions including 5 hPSC lines.

Recent evidence links Wnt signaling and glycolytic activities during hPSC differentiation into mesoderm38,39. Consistent with these findings, changes in OMI variables on day 1 of CM differentiation (24 h after Wnt activation, Fig. 1) and with known metabolic inhibitors in stem cells together with lactate and glucose assays (Fig. 1l–o, Supplementary Fig. 7) indicate that changes in OMI variables are due to increased glycolytic activity on day 1 of CM differentiation. Considering the important role of Wnt signaling activation in mesoderm and CM differentiation11, and embryonic development40, greater changes in OMI variables in the high differentiation efficiency condition could indicate more glycolytic activity due to successful Wnt activation compared to the low differentiation efficiency condition (Fig. 1c–k, Supplementary Fig. 1). Taken together, these results reveal that autofluorescence imaging can separate CM differentiation efficiencies at an early stage based on metabolic changes (Fig. 3b–e).

At the end of our differentiation process, some cells were not positive for cTnT and therefore were not CMs. Previous studies have shown that these non-CMs at the end of the differentiation process are primary cardiac-like fibroblasts together with a small portion of non-differentiated hPSCs41. hPSC-derived CMs exhibit distinct metabolism from other hPSC-derived non-CMs42. Co-culture of cardiac fibroblasts and CMs can induce fibroblast glycolytic activity and lactate secretion from fibroblasts43. Co-culture of cardiac fibroblasts and CMs also promotes a more mature phenotype in CMs along with increased reliance on oxidative phosphorylation41. Similarly, differences in NAD(P)H lifetime variables between CMs and non-CMs on day 8 (Fig. 4h) are consistent with decreased glycolytic activity in the CMs (Supplementary Fig. 7). These results further confirm that autofluorescence imaging can distinguish the distinct metabolic activities between hPSC-derived CMs and other non-CMs with the NKX2.5-EGFP reporter line. OMI distinguished different cell populations at multiple time-points in this differentiation protocol, with larger differences between low and high differentiation efficiencies on day 8 than on day 1. Day 1 cells are mainly primitive streak whereas cells on day 8 are at the end of differentiation and exhibit the glycolytic activities of fetal/newborn CMs44. Therefore, larger differences are expected in OMI between CMs and non-CMs at day 8 compared to low and high differentiation efficiencies on day 1. OMI differences between low and high differentiation efficiencies at multiple days in this protocol indicates that this technology could continuously monitor stem cell differentiation stages.

We have demonstrated that autofluorescence imaging can resolve metabolic changes in CM differentiation and predict the differentiation outcome at early time points. However, our method has limitations. The differentiation efficiency of hPSCs is susceptible to cell line variability, cell culture microenvironment, and differentiation protocol45. We note that the differentiation efficiency measured from flow cytometry in our experiments was not higher than 90%. This may be due to photo-toxicity during the imaging process that may moderately interrupt CM differentiation. In future studies, good manufacturing practice standards could be applied to optimize the evaluation process and minimize the interruption on differentiation. Additionally, OMI relies on only two metabolites, NAD(P)H and FAD, that do not comprehensively characterize cellular metabolic activities. More mechanistic studies together with other assays, including metabolite liquid chromatography–mass spectrometry29, NMR spectrometry46, single-cell RNASeq47, and quantitative proteomics48, need to be performed to reveal the relationship between metabolic dynamics and hPSC differentiation into CMs. Additionally, alternative differentiation protocols will require algorithms trained on OMI data in these new conditions to robustly classify differentiation efficiencies.

Overall, we developed a non-invasive method to predict the efficiency of hPSC differentiation into CMs at early differentiation stages. hPSCs hold great promise for regenerative medicine and pharmaceutical development, but large-scale cell manufacturing suffers from variability across hPSC lines and cell culture conditions. Our studies indicate that autofluorescence can predict CM differentiation efficiency at an early stage, which could enable real-time and/or in-line monitoring during cell manufacturing. This method could lower manufacturing costs and personnel time by flagging samples for timely interventions. Similar technologies could also impact other areas of regenerative cell manufacturing. A few studies have demonstrated that intravital autofluorescence imaging can monitor cellular metabolic activities, including tumor treatment resposne49 and heterogeneity of tumor tissues50. Therefore, the methods described in the current study could be used to track stem cell differentiation in vivo, with applications in label-free assessment of stem cell-generated tissue integration for in vivo tissue repair.

## Methods

### hPSC culture and cardiomyocyte differentiation

Human H9 and H13 embryonic stem cells51, human IMR90-4 and 19-9-11 induced pluripotent stem cells52, and NKX2.5EGFP/+ hPSCs36 were maintained on Matrigel (Corning)-coated surfaces in mTeSR1 (STEMCELL Technologies) as previously described53. CM differentiation was performed as described previously11. A step-by-step protocol describing the differentiation method can be found at Protocol Exchange (DOI: 10.21203/rs.3.pex-1571/v1). Different cell seeding densities and different concentrations of CHIR99021 were applied to manipulate differentiation efficiency. Briefly, hPSCs were singularized with Accutase (Thermo Fisher Scientific) and plated onto Matrigel-coated plates at a density ranging from of 2.9 × 104 cells/cm2 to 5.7 × 105 cells/cm2 (1.0 × 105 cells to 2.0 × 106 cells per well of a 12-well plate) in mTeSR1 supplemented with 10 µM Rho-associated protein kinase (ROCK) inhibitor Y-27632 (Selleckchem) 2 days before initiating differentiation. Differentiation was initiated by Wnt signaling activation with 8–12 µM CHIR99021 (Selleckchem) on day 0, followed by inhibition of Wnt signaling with 5 µM IPW2 on day 3.

### Flow cytometry

Cells on differentiation day 12 were disassociated with Accutase, fixed in 1% PFA for 15 min at room temperature, and then blocked with 0.5% bovine serum albumin (BSA) with 0.1% Triton X-100. Cells were then stained with primary antibody anti-cTnT (Lab Vision; 1:200) and secondary antibody (Thermo Fisher; goat anti-mouse, Alexa Fluor 488; 1:500) in 0.5% BSA with 0.1% Triton X-100. Data were collected on a FACSCalibur flow cytometer and analyzed with FlowJo. Data were collected from three biological replicates and presented as means ± SEM. cTnT positive percentage was rounded up at one decimal place.

### Lactate and glucose assays

After the first 24 h of differentiation, cell culture media were collected from three biological replicates for low and high differentiation efficiency conditions, respectively. Cell culture media were used for lactate and glucose assays following the kit instructions (Biovision, Lactate colorimetric assay kit and Glucose colorimetric assay kit). Absorbance was read by a plate reader at 570 nm.

Fluorescence lifetime imaging (FLIM) was performed by an Ultima two-photon imaging system (Bruker) composed of an ultrafast tunable laser source (Insight DS+, Spectra Physics) coupled to a Nikon Ti-E inverted microscope with time-correlated single photon counting electronics (SPC-150, Becker & Hickl, Berlin, Germany). The ultrafast tunable laser source enables sequential excitation of NAD(P)H at 750 nm and FAD at 890 nm. NAD(P)H and FAD emission was isolated using 440/80 nm and 550/100 nm bandpass filters (Chroma), respectively. The laser power at the sample for NAD(P)H and FAD excitation was approximately 2.3 mW and 7.9 mW, respectively. Fluorescence lifetime decays with 256 time bins were acquired across 256 × 256 pixel images with a pixel dwell time of 4.8 µs and an integration period of 60 s. All samples were illuminated through a 40×/1.15 NA objective (Nikon). FLIM was performed on differentiation day 0 (immediately pre-treatment with CHIR99021, a Wnt signaling activator), day 1 (24 h post-treatment with CHIR99021), day 3 (immediately pre-treatment with IWP2, a Wnt signaling inhibitor), and day 5 (48 h post-treatment with IWP2). For NKX2.5EGFP/+ hPSCs, day 8 NAD(P)H lifetime variables were also collected. Two-photon excitation of NKX2.5-EGFP was performed at 890 nm and emission was collected with a 550/100 nm bandpass filter. A 500LP dichroic mirror was used. For the 2DG experiment, H9 embryonic stem cells were imaged before and 2 h after 10 mM 2DG treatment, respectively. For the rotenone experiment, H9 embryonic stem cells were imaged before and 15 min after 10 μM rotenone treatment, respectively. The instrument response function was acquired from the second harmonic generated signal of urea crystals at 890 nm and was measured for each imaging session. A step-by-step protocol describing the imaging process can be found at Protocol Exchange (https://doi.org/10.21203/rs.3.pex-1571/v1).

### Image analysis

Lifetime images of NAD(P)H and FAD were analyzed via SPCImage software (Becker & Hickl). Two-component decays were calculated by the following equation22: $${{{{{\mathrm{I}}}}}}({{{{{\mathrm{t}}}}}})=\alpha_1e^{-t/t_1}+\alpha_2 e^{-t/t_2}+{{{{{\mathrm{C}}}}}}$$. Fluorescence intensity images were generated by integrating photon counts over the per-pixel fluorescence decays. For FLIM analysis of cells from differentiation day 0 to day 5, pixels were binned to 1 (3 × 3 pixels) to achieve good statistics for fluorescence decay fitting. Similarly, for NKX2.5-EGFP NAD(P)H lifetimes on day 8, pixels were binned to 2 (5 × 5 pixels). The per-pixel ratio of NAD(P)H fluorescence intensity to FAD intensity was calculated to determine optical redox ratio. ASC files of FLIM variables were exported from SPCImage, then converted into TIF with ImageJ, and these TIF were imported to CellProfiler. A customized CellProfiler pipeline was used to segment individual cell cytoplasms54. Cytoplasm masks were applied to all images to determine single-cell optical redox ratio and NAD(P)H and FAD fluorescence lifetime variables. Fluorescence lifetime variables consist of the mean lifetime (τm = α1τ1 + α2τ2), free- and protein-bound lifetime components (τ1 and τ2 for NAD(P)H, and τ2 and τ1 for FAD, respectively), and their fractional contributions (α1 and α2; where α1 + α2 = 1) for each individual cell cytoplasm. A total 13 OMI variables were analyzed for each cell cytoplasm: FAD intensity, FAD α1, FAD α2, FAD τ1, FAD τ2, and FAD τm; NAD(P)H intensity, NAD(P)H α1, NAD(P)H α2, NAD(P)H τ1, NAD(P)H τ2, and NAD(P)H τm; optical redox ratio$$=\frac{{{{{{{\rm{NAD}}}}}}}({{{{{\rm{P}}}}}}){{{{{{\rm{H}}}}}}\; {{{{{\rm{intensity}}}}}}}}{{{{{{{\rm{FAD}}}}}}\; {{{{{\rm{intensity}}}}}}}}$$. The optical redox ratio is the relative fluorescence intensities of NAD(P)H and FAD and provides an optical measurement of the redox state of the cell55,56,57. Different optical redox ratio definitions with either NAD(P)H or FAD in the numerator can be found in the literature55,56,57. Here, we use NAD(P)H/FAD as the optical redox ratio.

The phasor plot of lifetime decays for enhanced green fluorescent protein (EGFP) and NAD(P)H was performed as previously described58. Briefly, phasor lifetime plots are derived from a Fourier transformation of fluorescence lifetime decay curves by a custom algorithm. The fluorescence lifetime of each pixel in the image is presented in a 2D phasor plot with the unitless horizontal axis (G) and the vertical axis (S).

### UMAP clustering

Clustering of cells across all days and differentiation efficiency conditions was represented using UMAP. UMAP dimensionality reduction was performed on all 13 OMI variables (optical redox ratio, NAD(P)H τm, τ1, τ2, α1, α2, and intensity; FAD τm, τ1, τ2, α1, α2, and intensity) for projection in 2D space. The following parameters were used for UMAP visualizations: “n _neighbors”: 10; “min_dist”: 0.3, “metric”: cosine or euclidean, “n_components”: 2.

### Classification methods

Logistic regression classifiers were trained to distinguish cells at low (< 50% cTnT+ on day 12) and high (≥ 50% cTnT+ on day 12) differentiation efficiency 1 day post-treatment with CHIR99021. Consistent separation of day 1 UMAP clusters from all other days across differentiation conditions prompted classification of single-cell autofluorescence data from day 1 differentiation. All day 1 OMI data were partitioned into two datasets from two independent biological replicates (dataset 1 and dataset 2). Dataset 1 was randomly partitioned into training and validation datasets at the proportions of 80% and 20%, respectively (n = 8974 cells in the training set, n = 2244 cells in the validation set). Dataset 2 was used to independently evaluate trained classifiers for predicting known differentiation efficiencies (n = 19,245 cells). Chi-squared variable selection was used to evaluate classification accuracy as a function of the number of training variables. Variable weights for OMI variables were extracted to determine the contribution of each variable to the trained logistic regression model. Receiver operating characteristic (ROC) curves were generated to evaluate the logistic regression model performance on classification of test set data. Support vector machine and random forest classifiers were also trained to classify low and high differentiation efficiencies on day 1 to determine whether classification performance was dependent on the chosen model. Training and test set partitioning and variable selection methods for support vector machine and random forest classifiers were identical to those reported for the logistic regression model.

### Z-score hierarchical clustering

Z-score of each OMI variable for each condition was calculated across all 15 conditions. Z-score = $$\frac{{\mu }_{{observed}}-{\mu }_{{row}}}{{{{{{{\rm{\sigma }}}}}}}_{{row}}}$$, where μobserved is the mean value of each variable for each condition; μrow is the mean value of each variable for all 15 conditions together, and σrow is the standard deviation of each variable across all 15 conditions. Heatmaps of z-scores for all OMI variables were generated to visualize differences in each variable between low and high differentiation efficiency conditions at day 0 and day 1. Dendrograms show clustering based on the similarity of average Euclidean distances across all variable z-scores. Heatmaps and associated dendrograms were generated in R (heatmap.2, gplots package).

### Statistics

Data for OMI variables are presented as mean with 95% CI. Data for flow cytometry are presented as mean ± SEM. Statistical significance was determined by Student’s T-test (two-tailed) between two groups. Three or more groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc tests. P < 0.05 was considered statistically significant and indicated in the figures.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

The authors declare that all relevant data supporting the findings of this study are available within the article and its Supplementary Information files. Original single cell OMI data are provided with this paper. Source data are provided and all Excel files used to generate and support the results from the associated code have been deposited in the following repository: https://github.com/skalalab/cardiomyocyte_differentiation (https://doi.org/10.5281/zenodo.5046151). A step-by-step protocol describing the differentiation method can be found at Protocol Exchange (https://doi.org/10.21203/rs.3.pex-1571/v1). Source data are provided with this paper.

## Code availability

All the code for generating UMAP, z-score heatmap, and classification results have been deposited in the following repository: https://github.com/skalalab/cardiomyocyte_differentiation (https://doi.org/10.5281/zenodo.5046151).

## References

1. 1.

Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017).

2. 2.

Abouna, G. M. In Transplantation Proceedings, Vol. 40, 34–38 (Elsevier, 2008).

3. 3.

Lai, R. C., Chen, T. S. & Lim, S. K. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen. Med. 6, 481–492 (2011).

4. 4.

Tabar, V. & Studer, L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat. Rev. Genet. 15, 82–92 (2014).

5. 5.

Mohamed, T. M. et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell 173, 104–116. e112 (2018).

6. 6.

Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785–798 (2013).

7. 7.

Qian, T. et al. Directed differentiation of human pluripotent stem cells to blood-brain barrier endothelial cells. Sci. Adv. 3, e1701679 (2017).

8. 8.

Rezania, A. et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32, 1121 (2014).

9. 9.

Kattman, S. J. et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228–240 (2011).

10. 10.

Burridge, P. W., Keller, G., Gold, J. D. & Wu, J. C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16–28 (2012).

11. 11.

Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl Acad. Sci. USA 109, E1848–E1857 (2012).

12. 12.

Yoshida, Y. & Yamanaka, S. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell–based regeneration. Circulation 122, 80–87 (2010).

13. 13.

Moretti, A. et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397–1409 (2010).

14. 14.

Liang, P. et al. Drug screening using a library of human induced pluripotent stem cell–derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677–1691 (2013).

15. 15.

Braam, S. R., Passier, R. & Mummery, C. L. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol. Sci. 30, 536–545 (2009).

16. 16.

Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).

17. 17.

Huo, J. et al. Evaluation of batch variations in induced pluripotent stem cell-derived human cardiomyocytes from 2 major suppliers. Toxicol. Sci. 156, 25–38 (2017).

18. 18.

Sullivan, S. et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen. Med. 13, 859–866 (2018).

19. 19.

Malandraki-Miller, S., Lopez, C. A., Al-Siddiqi, H. & Carr, C. A. Changing metabolism in differentiating cardiac progenitor cells—can stem cells become metabolically flexible cardiomyocytes? Front. Cardiovasc. Med. 5, 119 (2018).

20. 20.

Skala, M. C. et al. In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia. Proc. Natl Acad. Sci. USA 104, 19494–19499 (2007).

21. 21.

Nakashima, N., Yoshihara, K., Tanaka, F. & Yagi, K. Picosecond fluorescence lifetime of the coenzyme of d-amino acid oxidase. J. Biol. Chem. 255, 5261–5263 (1980).

22. 22.

Lakowicz, J. R., Szmacinski, H., Nowaczyk, K. & Johnson, M. L. Fluorescence lifetime imaging of free and protein-bound NADH. Proc. Natl Acad. Sci. USA 89, 1271–1275 (1992).

23. 23.

Meleshina, A. V. et al. Probing metabolic states of differentiating stem cells using two-photon FLIM. Sci. Rep. 6, 1–11 (2016).

24. 24.

Rice, W. L., Kaplan, D. L. & Georgakoudi, I. Two-photon microscopy for non-invasive, quantitative monitoring of stem cell differentiation. PLoS ONE 5, e10075 (2010).

25. 25.

Meleshina, A. V. et al. Two-photon FLIM of NAD (P) H and FAD in mesenchymal stem cells undergoing either osteogenic or chondrogenic differentiation. Stem Cell Res. Ther. 8, 1–10 (2017).

26. 26.

Rodimova, S. A. et al. Metabolic activity and intracellular pH in induced pluripotent stem cells differentiating in dermal and epidermal directions. Methods Appl. Fluoresc. 7, 044002 (2019).

27. 27.

Uchugonova, A. Multiphoton autofluorescence lifetime imaging of induced pluripotent stem cells. J. Biomed. Opt. 22, 066018 (2017).

28. 28.

Zhou, H. et al. Non-invasive optical biomarkers distinguish and track the metabolic status of single hematopoietic. Stem Cells Iscience 23, 100831 (2020).

29. 29.

Gu, W. et al. Glycolytic metabolism plays a functional role in regulating human pluripotent stem cell state. Cell Stem Cell 19, 476–490 (2016).

30. 30.

Yanes, O. et al. Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 6, 411 (2010).

31. 31.

Laco, F. et al. Unraveling the inconsistencies of cardiac differentiation efficiency induced by the GSK3β inhibitor CHIR99021 in human pluripotent stem cells. Stem Cell Rep. 10, 1851–1866 (2018).

32. 32.

Brown, J. Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metabolism 11, 1098–1112 (1962).

33. 33.

Li, N. et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278, 8516–8525 (2003).

34. 34.

Zhang, J., Nuebel, E., Daley, G. Q., Koehler, C. M. & Teitell, M. A. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 11, 589–595 (2012).

35. 35.

McInnes, L., Healy, J. & Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv:1802.03426. Preprint at https://arxiv.org/abs/1802.03426 (2018).

36. 36.

Schwach, V. et al. A COUP-TFII human embryonic stem cell reporter line to identify and select atrial cardiomyocytes. Stem Cell Rep. 9, 1765–1779 (2017).

37. 37.

Nakabayashi, T., Wang, H.-P., Kinjo, M. & Ohta, N. Application of fluorescence lifetime imaging of enhanced green fluorescent protein to intracellular pH measurements. Photochem. Photobiol. Sci. 7, 668–670 (2008).

38. 38.

Rasmussen, M. L., Ortolano, N. A., Romero-Morales, A. I. & Gama, V. Wnt signaling and its impact on mitochondrial and cell cycle dynamics in pluripotent stem cells. Genes 9, 109 (2018).

39. 39.

Oginuma, M. et al. Intracellular pH controls WNT downstream of glycolysis in amniote embryos. Nature 584, 98–101 (2020).

40. 40.

Kahn, M. Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 13, 513–532 (2014).

41. 41.

Biendarra-Tiegs, S. M., Clemens, D. J., Secreto, F. J. & Nelson, T. J. Human induced pluripotent stem cell-derived non-cardiomyocytes modulate cardiac electrophysiological maturation through connexin 43-mediated cell-cell interactions. Stem cells Dev. 29, 75–89 (2020).

42. 42.

Tohyama, S. et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127–137 (2013).

43. 43.

Gizak, A., McCubrey, J. A. & Rakus, D. Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure. Aging (Albany NY) 12, 3388 (2020).

44. 44.

Lopaschuk, G. D. & Jaswal, J. S. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J. Cardiovasc. Pharmacol. 56, 130–140 (2010).

45. 45.

Chen, K. G., Mallon, B. S., McKay, R. D. & Robey, P. G. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell 14, 13–26 (2014).

46. 46.

Bhute, V. J. et al. Metabolomics identifies metabolic markers of maturation in human pluripotent stem cell-derived cardiomyocytes. Theranostics 7, 2078 (2017).

47. 47.

Guo, J. et al. Chromatin and single-cell RNA-seq profiling reveal dynamic signaling and metabolic transitions during human spermatogonial stem cell development. Cell Stem Cell 21, 533–546. e536 (2017).

48. 48.

Williamson, A. J. et al. Quantitative proteomics analysis demonstrates post-transcriptional regulation of embryonic stem cell differentiation to hematopoiesis. Mol. Cell. Proteom. 7, 459–472 (2008).

49. 49.

Shah, A. T., Diggins, K. E., Walsh, A. J., Irish, J. M. & Skala, M. C. In vivo autofluorescence imaging of tumor heterogeneity in response to treatment. Neoplasia 17, 862–870 (2015).

50. 50.

Heaster, T. M., Heaton, A. R., Sondel, P. M. & Skala, M. C. Intravital metabolic autofluorescence imaging captures macrophage heterogeneity across normal and cancerous tissue. Front. Bioeng. Biotechnol. 9, 312 (2021).

51. 51.

Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).

52. 52.

Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).

53. 53.

Ludwig, T. E. et al. Feeder-independent culture of human embryonic stem cells. Nat. Methods 3, 637 (2006).

54. 54.

Walsh, A. J. & Skala, M. C. In Multiphoton Microscopy in the Biomedical Sciences XIV, Vol. 8948 89481M (International Society for Optics and Photonics, 2014).

55. 55.

Chance, B., Schoener, B., Oshino, R., Itshak, F. & Nakase, Y. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J. Biol. Chem. 254, 4764–4771 (1979).

56. 56.

Varone, A. et al. Endogenous two-photon fluorescence imaging elucidates metabolic changes related to enhanced glycolysis and glutamine consumption in precancerous epithelial tissues. Cancer Res. 74, 3067–3075 (2014).

57. 57.

Ostrander, J. H. et al. Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status. Cancer Res. 70, 4759–4766 (2010).

58. 58.

Digman, M. A., Caiolfa, V. R., Zamai, M. & Gratton, E. The phasor approach to fluorescence lifetime imaging analysis. Biophysical J. 94, L14–L16 (2008).

## Acknowledgements

This work was supported by the Morgridge Institute for Research. Some of the imaging optimization experiments were supported by the NIH (U01 EY032333, R01 CA211082, R01 CA205101, R01 CA185747) and NSF Center for Cell manufacturing Technologies (EEC-1648035). We thank Matthew Stefely for the help on figure illustration. We thank Jens Eickhoff for the useful suggestions on statistics.

## Author information

Authors

### Contributions

The project was conceived by T.Q. and M.C.S. The experiments were designed by T.Q. and M.C.S., and were carried out by T.Q. Data analysis was performed by T.Q., T.M.H., A.R.H., K.S. and K.S. The manuscript was written by T.Q., T.M.H. and M.C.S.

### Corresponding authors

Correspondence to Tongcheng Qian or Melissa C. Skala.

## Ethics declarations

### Competing interests

The authors declare no competing interests.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Qian, T., Heaster, T.M., Houghtaling, A.R. et al. Label-free imaging for quality control of cardiomyocyte differentiation. Nat Commun 12, 4580 (2021). https://doi.org/10.1038/s41467-021-24868-1

• Accepted:

• Published: